SOLICITATION NOTICE
A -- Laboratory Support for Protocol 2009-423
- Notice Date
- 6/22/2010
- Notice Type
- Presolicitation
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, Station Support/Simplified Acquisitions, 31 Center Drive, Room 1B59, Bethesda, Maryland, 20892
- ZIP Code
- 20892
- Solicitation Number
- 1649105
- Archive Date
- 7/16/2010
- Point of Contact
- Jasmine D Snoddy, Phone: 301 594 1571
- E-Mail Address
-
snoddyj@mail.nih.gov
(snoddyj@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- This is a notice of intent, not a request for a proposal. A solicitation document will not be issued and proposals will not be requested. The National Institute on Drug Abuse (NIDA) Station Support/Simplified Acquisition (SS/SA) Branch, on behalf of the National Institute of Aging (NIA) intends to negotiate and award a sole source purchase order to The Trustees of the University of Pennsylvania, 3451Walnut Street, Room P221, Franklin Building, Philadelphia, PA, 19104-6205 to provide laboratory support for the NIA Protocol 2009-423 (“A clinical trial of Exendin-4 for the treatment of Alzheimer’s disease”), in regards to the measurement of specific biomarkers of Alzheimer’s disease. The NIA will provide to the contractor de-identified CSF and plasma samples from study participants, obtained during the screening visit and the 6, 12, 18, 24, and 36-month study visits. Each sample will be labeled/marked by a site name (NIA), study identification number, a study visit number the type of biofluid contained and the date and time of acquisition. The contractor will obtain and report results of measurements performed on samples obtained according to the schedule below. These measurements will be performed according to established laboratory standards for quality control to ensure validity and accuracy of the results. In more detail, the following kinds of samples will be sent to the contractor. A.Screening Visit (Up to 230 participants) The NIA will send individuals’ participants’ CSF and plasma samples obtained during their screening visit. Results of CSF biomarker measurement (as detailed below) from the screening visit will determine participants’ eligibility for the clinical trial. Therefore, the contractor should report the results for CSF within one month (30 days) from the receipt of each sample. The contractor should report the results for plasma within three months (90) days from the receipt of the batch. •CSF samples (5 ml) i.Measurement of the levels of the amyloid beta peptide ii.Measurement of the levels of the total tau protein iii.Measurement of the levels of the tau protein phosphorylated on threonine 181 •Plasma Samples (5ml) i.Measurement of the levels of the amyloid beta peptide and the amyloid beta peptide and of the ratio B.6, 12, 24 and 36 month study visits (Up to 150 participants) The NIA will send to the contractor batched plasma samples obtained during these visits once every month. The contractor should report the results for plasma within three months (90 days) from the receipt of the batch. •Plasma samples (5 ml) ii.Measurement of the levels of the amyloid beta peptide and the amyloid beta peptide and of the ratio C.18 month study visit (Up to 150 participants) The NIA will send to the contractor batched CSF and plasma samples obtained during this visit once every month. The contractor should report the results for CSF and plasma within three months (90 days) from the receipt of the batch. • CSF samples (5 ml) iii.Measurement of the levels of the amyloid beta peptide iv.Measurement of the levels of the total tau protein v.Measurement of the levels of the tau protein phosphorylated on threonine 181 •Plasma samples (5 ml) i.Measurement of the levels of the amyloid beta peptide and the amyloid beta peptide and of the ratio The period of performance will be July 5, 2010-July 4, 2011 with 5 option years. University of Pennsylvania is the only known source for conducting the biomarker measurements in CSF and plasma for the study “A clinical trial of Exendin-4 for the treatment of Alzheimer’s disease. The source has also been approved by several protocols. The acquisition is being conducted under simplified acquisition using FAR 12 procedures and exempt from the requirement of FAR Part 6, Competition Requirement. This notice of intent is not a request for competitive proposals. Interested parties may identify their interest and capabilities in response to this synopsis. The determination by the Government not to compete the proposed contract based upon responses to this notice is solely with the discretion of the Government. Comments to this announcement, referencing synopsis number 1649105 may be submitted to the NIDA, Station Support/Simplified Acquisition Branch, 31 Center Drive, Room 1B59, Bethesda, Maryland 20892-2080 and Attention: Jasmine Snoddy, Contract Specialist.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-2/1649105/listing.html)
- Place of Performance
- Address: Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN02184358-W 20100624/100622235146-651b49d5175bffc05f9d409bc9df81f3 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |